Comparison of the pharmacokinetics and safety of a paclitaxel injection NK and Taxol injection in breast cancer patients

A paclitaxel injection NK (NK) is a generic product containing the same amount of ingredient as a Taxol Injection. We examined the pharmacokinetics and safety of NK compared to the original product in breast cancer patients. As a result, the transition of plasma paclitaxel concentration and pharmaco...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 36; no. 2; p. 247
Main Authors Sagara, Yoshiaki, Rai, Yoshiaki, Sagara, Yoshiatsu, Matsuyama, Yoshito, Baba, Shinichi, Tamada, Shugo, Sagara, Yasuaki, Ando, Mitsutake
Format Journal Article
LanguageJapanese
Published Japan 01.02.2009
Subjects
Adult
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Breast Neoplasms - drug therapy
Humans
Infusions, Intravenous
Middle Aged
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Paclitaxel - pharmacokinetics
Paclitaxel - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:A paclitaxel injection NK (NK) is a generic product containing the same amount of ingredient as a Taxol Injection. We examined the pharmacokinetics and safety of NK compared to the original product in breast cancer patients. As a result, the transition of plasma paclitaxel concentration and pharmacokinetic parameter in NK and the original drug were almost equal, which suggested that these products were bioequivalent. In adjuvant therapy, there was no significant difference in adverse events reported, and these products were approximately equally safe.
ISSN:0385-0684